| Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial RS Herbst, P Baas, DW Kim, E Felip, JL Pérez-Gracia, JY Han, J Molina, ... The Lancet 387 (10027), 1540-1550, 2016 | 6938 | 2016 |
| Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients RS Herbst, JC Soria, M Kowanetz, GD Fine, O Hamid, MS Gordon, ... Nature 515 (7528), 563-567, 2014 | 5564 | 2014 |
| The biology and management of non-small cell lung cancer RS Herbst, D Morgensztern, C Boshoff Nature 553 (7689), 446-454, 2018 | 3985 | 2018 |
| Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non–small cell lung cancer: a randomized trial MG Kris, RB Natale, RS Herbst, TJ Lynch Jr, D Prager, CP Belani, ... Jama 290 (16), 2149-2158, 2003 | 3454 | 2003 |
| Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non … DH Johnson, L Fehrenbacher, WF Novotny, RS Herbst, JJ Nemunaitis, ... Journal of Clinical Oncology 22 (11), 2184-2191, 2004 | 2509 | 2004 |
| Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2 RS Herbst, G Giaccone, JH Schiller, RB Natale, V Miller, C Manegold, ... | 2334 | 2004 |
| Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. G Giaccone, RS Herbst, C Manegold, GV Scagliotti, R Rosell, V Miller, ... | 2297 | 2004 |
| Longitudinal analyses reveal immunological misfiring in severe COVID-19 C Lucas, P Wong, J Klein, TBR Castro, J Silva, M Sundaram, ... Nature 584 (7821), 463-469, 2020 | 2165 | 2020 |
| Review of epidermal growth factor receptor biology RS Herbst International Journal of Radiation Oncology* Biology* Physics 59 (2), S21-S26, 2004 | 1952 | 2004 |
| Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study NM Kuderer, TK Choueiri, DP Shah, Y Shyr, SM Rubinstein, DR Rivera, ... The Lancet, 2020 | 1930 | 2020 |
| Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non–small-cell lung cancer treated with chemotherapy … DA Eberhard, BE Johnson, LC Amler, AD Goddard, SL Heldens, ... Journal of clinical oncology 23 (25), 5900-5909, 2005 | 1850 | 2005 |
| TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non–small-cell lung cancer RS Herbst, D Prager, R Hermann, L Fehrenbacher, BE Johnson, ... Journal of clinical oncology 23 (25), 5892-5899, 2005 | 1840 | 2005 |
| Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer YL Wu, M Tsuboi, J He, T John, C Grohe, M Majem, JW Goldman, ... New England Journal of Medicine, 2020 | 1551 | 2020 |
| Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC RS Herbst, G Giaccone, F de Marinis, N Reinmuth, A Vergnenegre, ... New England Journal of Medicine 383 (14), 1328-1339, 2020 | 1385 | 2020 |
| Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study K Shedden, JMG Taylor, SA Enkemann, MS Tsao, TJ Yeatman, ... Nature medicine 14 (8), 822, 2008 | 1141 | 2008 |
| Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial SB Goldberg, SN Gettinger, A Mahajan, AC Chiang, RS Herbst, M Sznol, ... The lancet oncology 17 (7), 976-983, 2016 | 1057 | 2016 |
| The BATTLE trial: personalizing therapy for lung cancer ES Kim, RS Herbst, II Wistuba, JJ Lee, GR Blumenschein, A Tsao, ... Cancer discovery 1 (1), 44-53, 2011 | 1050 | 2011 |
| An epithelial–mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor … LA Byers, L Diao, J Wang, P Saintigny, L Girard, M Peyton, L Shen, Y Fan, ... Clinical cancer research 19 (1), 279-290, 2013 | 1048 | 2013 |
| Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study … GD Demetri, M Kris, J Wade, L Degos, D Cella Journal of Clinical Oncology 16 (10), 3412-3425, 1998 | 1030 | 1998 |
| Antiemetics: American Society of Clinical Oncology clinical practice guideline update E Basch, AA Prestrud, PJ Hesketh, MG Kris, PC Feyer, MR Somerfield, ... Journal of Clinical Oncology 29 (31), 4189, 2011 | 1012 | 2011 |
